Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Aug 12;286(39):34457–34467. doi: 10.1074/jbc.M111.229633

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 7. — Attenuation of body weight loss (A) and delay in onset of weight loss (B) after treatment with MC1 and PHF1. A, repeated-measures ANOVA indicated that there was a significant Day × Group interaction F(50,900) = 3.29, p < 0.0001 with both MC1 and PHF1 treatment reducing the weight loss from day 85 onward. Univariate planned comparisons revealed significant group effect from day 85 onward, p < 0.03. Post hoc Dunnett test compared with control antibody (Ab)-treated group: Day 85: F(2,36) = 4.07, p = 0.03, MC1 p = 0.01, PHF1 p = 0.03; Day 88: F(2,36) = 3.75, p = 0.03, MC1 p = 0.01, PHF1 p = 0.04; Day 93: F(2,36) = 4.00, p = 0.03, MC1 p = 0.009, PHF1 p = 0.05. In all cases; *, p < 0.05 versus control Ab-treated. Data are based on n = 13 mice per group. B, illustrates the mean day of onset of body weight loss in P301S mice. Results indicated that both MC1 and PHF1 treatment delayed the onset of weight loss. One-way ANOVA F(2,36) = 9.33, p < 0.001. Post hoc Dunnett test compared with control Ab-treated group; ***, p < 0.005. Data are based on 13 mice per group.